Global Head – Business Development
David Gibson is the Global Head of Business Development at Biocon Biologics, where he is leading the Company’s efforts in partnering, in/out-licensing assets, and identifying regional commercial partners in collaboration with the Portfolio Strategy and Commercial Teams.
Dave, who joined Biocon Biologics in 2023, brings with him over 24 years of experience in leadership roles spanning across various fields, including Business Development, Product Development, Venture Capital, Manufacturing and R&D. He has previously worked at Big Pharma companies such as Wyeth and GSK.
He has a successful track record of leading large transactions, including the divestment, acquisition, and licensing of R&D and manufacturing assets, clinical and commercial stage programs, and platform technologies. He is skilled in building strategic alliances, negotiating complex deals, and unlocking value from innovation.
Most recently, Dave served as the Vice President and Head of Business Development for GSK’s Global Supply Chain. In this role, he was responsible for leading the design and implementation of the future pharma manufacturing network. He was also accountable for divesting a significant number of manufacturing businesses globally and identifying long-term strategic partners to deliver significant value to GSK.
He also served as an Advisory Board member of the Gateway UCC Innovation and Incubation Center. GatewayUCC acts as a catalyst for university-led entrepreneurship, fostering the development of knowledge-based indigenous spin-out companies that exploit university-generated intellectual property (IP).
Dave has specialized in Bioreaction Engineering and Genetics from Dublin City University, Ireland.